Immunization, Infections
Conditions
Keywords
immunology, Vaccine response
Brief summary
Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or trained immunity, which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years. The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine
Detailed description
Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or trained immunity, which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years. For example, research has shown that the live attenuated BCG vaccine induce non-specific trained immunity, enabling innate immune cells to remember their first encounter and improve their immune status during a second confrontation with similar or different agents. Other currently available live vaccines, such as BCG , could also train innate immune cells. The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine
Interventions
BIOLOGICALblood samples collection
blood samples collected at D0 ,W1, W5, M3 and M6
Sponsors
Institut Pasteur
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Age between 18 and 65 * Referred for immunisation against yellow fever and typhoid * Any person with indication for the following vaccinations : * Yellow fever * Typhoïd * Whose vaccination schedule includes two appointments 7 days apart * Whose state of health is compatible with a single 51 ml blood sample collection * Have consented to participate in the Ivory2 study * Benefiting from a Social Security plan or equivalent
Exclusion criteria
* Anyone with a contraindication to yellow fever and/or typhoid vaccination. * Any person who has been vaccinated against yellow fever and/or typhoid. * Anyone who has lived in an endemic area (≥ 1 year) and/or has a history of Typhoid. * Anyone who is unable to attend the visit 1-month after the typhoid vaccine injection. * Women claiming to be pregnant or breast-feeding * Anyone unable to give informed consent for participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunological profile of PBMCs, before and after yellow fever vaccination | 6 months | Cytokine production assays (e.g. TNFa, IL6, IL1b) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Description of the response to TyphimVi® vaccine | 6 months | ELISA-based quantification of Anti-Vi antibody level \>30 U/mL at week 5, and/or fold increase ≥2 compared with pre-vaccination IgG titer. |
Countries
France
Contacts
Primary ContactJessica Quintin, Dr
Backup ContactSandrine Fernandes Pellerin
Outcome results
None listed